Gene · 862
Papers4,591
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,801 to 1,820 of 4,591
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML). | Front Oncol | 2019 | 31681569 | PubTator, text mining | PubMed |
| Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells. | Front Immunol | 2019 | 31681270 | PubTator, text mining | PubMed |
| Clinical and genomic features of adult and paediatric acute leukaemias with ophthalmic manifestations. | BMJ Open Ophthalmol | 2019 | 31673633 | PubTator, text mining | PubMed |
| The functional mechanisms of mutations in myelodysplastic syndrome. | Leukemia | 2019 | 31673113 | PubTator, text mining | PubMed |
| Clonal hematopoiesis in human aging and disease. | Science | 2019 | 31672865 | PubTator, text mining | PubMed |
| TAF1 plays a critical role in AML1-ETO driven leukemogenesis. | Nat Commun | 2019 | 31664040 | PubTator, text mining | PubMed |
| Subdural Hygroma: A Morbid Complication of Intrathecal Chemotherapy in a Patient with B-Cell Acute Lymphocytic Leukemia. | Case Rep Hematol | 2019 | 31662916 | PubTator, text mining | PubMed |
| The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. | Int J Mol Sci | 2019 | 31661875 | PubTator, text mining | PubMed |
| Long Noncoding RNAs in Acute Myeloid Leukemia: Functional Characterization and Clinical Relevance. | Cancers (Basel) | 2019 | 31653018 | PubTator, text mining | PubMed |
| Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia. | Cancers (Basel) | 2019 | 31652787 | PubTator, text mining | PubMed |
| [Expression of Tim-3 on natural killer cells in patients with acute myeloid leukemia and its clinical significance]. | Zhonghua Xue Ye Xue Za Zhi | 2019 | 31648478 | PubTator, text mining | PubMed |
[Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation]. | Zhonghua Xue Ye Xue Za Zhi | 2019 | 31648470 | PubTator, text mining | PubMed |
| PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors. | Oncotarget | 2019 | 31645898 | PubTator, text mining | PubMed |
| Gene mutation profile and risk stratification in AML1‑ETO‑positive acute myeloid leukemia based on next‑generation sequencing. | Oncol Rep | 2019 | 31638252 | PubTator, text mining | PubMed |
| ASXL2 mutation is recurrent in non-de novo AML1-ETO-negative acute myeloid leukemia. | Ann Hematol | 2019 | 31637484 | PubTator, text mining | PubMed |
| Rare cytogenetic abnormalities and their clinical relevance in pediatric acute leukemia of Saudi Arabian population. | Mol Cytogenet | 2019 | 31632455 | PubTator, text mining | PubMed |
| A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients With GBM. | Front Genet | 2019 | 31632439 | PubTator, text mining | PubMed |
| Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation. | Cancer Immunol Immunother | 2019 | 31628525 | PubTator, text mining | PubMed |
| The role of exosomes and MYC in therapy resistance of acute myeloid leukemia: Challenges and opportunities. | Mol Aspects Med | 2019 | 31623866 | PubTator, text mining | PubMed |
| In Silico Genetics Revealing 5 Mutations in CEBPA Gene Associated With Acute Myeloid Leukemia. | Cancer Inform | 2019 | 31621694 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/862/papers?page=91